Unity Biotechnology

Unity Biotechnology's Chief Legal Officer, Nguyen Alexander Hieu, sold 149 shares at $1.29 each under a Rule 10b5-1 plan to cover tax obligations. He retains 24,723 shares, including RSUs. The company, with a market cap of $19.29 million, has more cash than debt and liquid assets exceeding short-term obligations, but is unprofitable with a P/E ratio of -0.96. Two analysts revised earnings upwards, and the stock, down 40.98% over a year, is near its 52-week low.

Unity Biotechnology's stock hits 52-week low at $1.15, down 38.54% in a year. Despite cash surplus over debt, the company faces financial hurdles with a -$13.4 million gross profit and -$27.91 million adjusted operating income. InvestingPro suggests a fair value of $1.74.

Unity Biotechnology has a 17-month cash runway with $34m cash and a $24m annual burn. Despite a 46% reduction in burn, its cash burn is 111% of its market cap, raising funding concerns.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of bots. Account usually reactivates within 24 hours; contact support if still disabled.

Unity Biotechnology's Q3 2024 Form 10-Q reports a net loss of $6.5 million, down from $14.8 million in Q3 2023, and $17.6 million for the first nine months of 2024, compared to $35.5 million in 2023. The company focuses on senolytic medicines, with UBX1325 showing positive results in DME and nAMD trials. Unity anticipates continued losses and seeks additional funding for clinical development and commercialization.

UNITY Biotechnology reported Q3 2024 financial results, highlighting a net loss of $6.5 million. The company discussed UBX1325's potential in diabetic macular edema (DME) and expects pivotal study results in 2025. Cash, cash equivalents, and marketable securities totaled $29.0 million as of September 30, 2024.

UNITY Biotechnology (UBX) reported Q3 2024 financial results, highlighting progress in developing UBX1325 for diabetic macular edema (DME). The company expects a pivotal study to be a non-inferiority trial comparing UBX1325 to aflibercept. Financial highlights include a cash position of $29.0 million, a net loss of $6.5 million, and reduced R&D expenses of $2.8 million. UNITY anticipates topline 24-week data in Q1 2025 and 36-week data in Q2 2025.

UNITY Biotechnology will host an in-person and virtual event on Oct 15, 2024, focusing on its Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) in DME. The event includes presentations on the senolytic therapeutic hypothesis, clinical development plans, and a retina expert roundtable. 24-week data expected Q1 2025, 36-week data Q2 2025.

UNITY Biotechnology will host an in-person and virtual event on October 15, 2024, focusing on its Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) in diabetic macular edema. The event includes presentations on the senolytic therapeutic hypothesis, clinical development plans, and a retina expert roundtable, followed by a live Q&A. 24-week data is expected in Q1 2025, with 36-week data in Q2 2025.